A patent review on HMGB1 inhibitors for the treatment of liver diseases

Introduction HMGB1 is a non-histone chromatin protein released or secreted from cells in response to tissue damage or infection. Extracellular HMGB1, as a crucial immunomodulatory factor, binds with several different receptors to innate inflammatory responses that aggravate acute and chronic liver diseases. The increased levels of HMGB1 have been reported in various liver diseases, highlighting that it represents a potential biomarker and druggable target for therapeutic development.